The impact of perceived volume limits on subcutaneous biologic drug development: an industry survey
6 affiliations
- 1Enable Injections, Inc., Cincinnati, Ohio, USA
- 2CMC and Drug Device Combination Products, WuXi Biologics USA, San Francisco, California
- 3Corporate Development, Crinetics Pharmaceuticals, San Diego, California
- 4Enveda Biosciences, Boulder, Colorado, USA
- 5Takeda Pharmaceuticals, Boston, Massachusetts, USA
- 6Pfizer, Inc, Andover, Massachusetts, USA
Abstract
As multiple large-volume subcutaneous (SC) biologics enter trials or gain approval, understanding how administration volume impacts biologic development is critical. While patients often prefer SC over intravenous administration, large-volume SC delivery adoption is hindered by the belief that SC delivery must be ≤3 mL without a permeation enhancer (PE). A 21-item online survey was conducted among professionals working in research and development; chemistry, manufacturing, and controls (CMC); portfolio strategy, new product planning; and combination products. Questions explored perceptions of SC administration volume limits, biologic deprioritization and abandonment, large-volume delivery considerations, and organizational approaches to revisiting deprioritized candidates. Eighty-eight participants completed the survey; 90.9% reported direct involvement in at least one project in which a biologic had been deprioritized or abandoned due to challenges achieving an SC volume of ≤3 mL. Respondents estimated that a weighted mean of 32.4% of relevant biologics had been abandoned and 28.9% had been deprioritized because of such challenges. Frequently selected reasons included limited experience with large-volume formulations or devices (29.5%), patient and/or healthcare provider preference (19.3%), and development costs or timelines (17.0%). Overall, 33.0% of respondents selected ≤3 mL as the maximum volume for SC infusion over several minutes without a PE. These findings indicate that perceived SC volume constraints may influence development decisions and highlight the importance of differentiating between device-related and physiological limits on SC administration volume. This study demonstrates that misconceptions about SC injection volume limits may lead to deprioritization or abandonment of viable assets during biologic development.
Related
- Occupational burnout in the UK film and television industry: A cross-sectional survey of mental health, job quality, perceived stigma, and sexual harassment
- The Hidden Impact: Participants’ Experiences in Troubled Teen Industry Programs
- Development of a tool to measure patient-oriented outcomes for Veterans with inflammatory arthritis initiating self-administered biologic therapies.
- Social Marketing Strategies in the Pharmaceutical Industry, Characteristics and Impact; a scoping review.
- Economic and organizational impact of oral versus intravenous and subcutaneous administration of hypomethylating agents in patients with acute myeloid leukemia not eligible for intensive chemotherapy in Spain
BibTeX
@article{desai2026impact,
title = {{The impact of perceived volume limits on subcutaneous biologic drug development: an industry survey}},
author = {Mehul Desai and Wei Chen and Maxwell Koobatian and Deepa Rajagopalan and Shirish Ingawale and Deep Bhattacharya},
journal = {Drug Delivery},
year = {2026},
month = nov,
doi = {10.1080/10717544.2026.2756024},
url = {https://doi.org/10.1080/10717544.2026.2756024},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - The impact of perceived volume limits on subcutaneous biologic drug development: an industry survey
AU - Mehul Desai
AU - Wei Chen
AU - Maxwell Koobatian
AU - Deepa Rajagopalan
AU - Shirish Ingawale
AU - Deep Bhattacharya
PY - 2026
DA - 2026/11/07
JO - Drug Delivery
DO - 10.1080/10717544.2026.2756024
UR - https://doi.org/10.1080/10717544.2026.2756024
AB - As multiple large-volume subcutaneous (SC) biologics enter trials or gain approval, understanding how administration volume impacts biologic development is critical. While patients often prefer SC over intravenous administration, large-volume SC delivery adoption is hindered by the belief that SC delivery must be ≤3 mL without a permeation enhancer (PE). A 21-item online survey was conducted among professionals working in research and development; chemistry, manufacturing, and controls (CMC); portfolio strategy, new product planning; and combination products. Questions explored perceptions of SC administration volume limits, biologic deprioritization and abandonment, large-volume delivery considerations, and organizational approaches to revisiting deprioritized candidates. Eighty-eight participants completed the survey; 90.9% reported direct involvement in at least one project in which a biologic had been deprioritized or abandoned due to challenges achieving an SC volume of ≤3 mL. Respondents estimated that a weighted mean of 32.4% of relevant biologics had been abandoned and 28.9% had been deprioritized because of such challenges. Frequently selected reasons included limited experience with large-volume formulations or devices (29.5%), patient and/or healthcare provider preference (19.3%), and development costs or timelines (17.0%). Overall, 33.0% of respondents selected ≤3 mL as the maximum volume for SC infusion over several minutes without a PE. These findings indicate that perceived SC volume constraints may influence development decisions and highlight the importance of differentiating between device-related and physiological limits on SC administration volume. This study demonstrates that misconceptions about SC injection volume limits may lead to deprioritization or abandonment of viable assets during biologic development.
SN - 1071-7544
SN - 1521-0464
ER -